Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IL-2 upgrades show promise at ASCO

Nature Biotechnology volume 40, pages 986–988 (2022)Cite this article

Companies pursue souped-up IL-2 candidates, undeterred by Nektar’s setback.

Undeterred by bempegaldesleukin’s demise, the industry is forging ahead with a diverse pipeline of designer IL-2–based agents — more than a dozen of which are now in the clinic — as developers hope to overcome the challenges that have kept the cytokine from its immuno-oncology promise (Table 1). Many companies are eyeing applications in autoimmunity, too. “There are a lot of good strategies that are out there,” says Marc Ernstoff, chief of the ImmunoOncology Branch at the US National Cancer Institute. “Each of the engineered IL-2–like drugs is unique — and I think each will have to be tested.”

Table 1 IL-2 therapies in oncology trials
Full size table

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Somerville, MA, USA

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. IL-2 upgrades show promise at ASCO. Nat Biotechnol 40, 986–988 (2022). https://doi.org/10.1038/s41587-022-01390-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01390-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing